Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia: a Double-blind Placebo-controlled Randomized Clinical Trial Assessing Treatment Efficacy and Safety.

NCT07638865 is registered in ClinicalTrials.gov with G.Gennimatas General Hospital as lead sponsor.

NCT NCT07638865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07638865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia: a Double-blind Placebo-controlled Randomized Clinical Trial Assessing Treatment Efficacy and Safety.
Lead sponsor
G.Gennimatas General Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
June 8, 2026
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostate enlargement, benign prostate hypertrophy(bph), benign prostate obstruction (bpo)